OnCo
companiesCompany

Northwest Biotherapeutics

Northwest Biotherapeutics developed the DCVax-L dendritic cell vaccine for glioblastoma and is seeking UK approval on contested phase 3 data.

DCVax-L MHRA application (December 2023) pending; manufacturing at Sawston, UK. Not FDA-approved.

Headquarters
Bethesda, MD, US
Type
cell therapy · NWBO
Website
nwbio.com

Products

1top
Phase 3Autologous dendritic cell vaccine (tumour lysate)
DCVax-L

A personalised vaccine made from the patient's own immune cells and tumour. Its 20-year-old phase 3 trial reported longer survival, but the way the result was analysed has divided the field.

Connected

2top

cancers

1
Glioma & glioblastoma

drugs

1
Phase 3Autologous dendritic cell vaccine (tumour lysate)
DCVax-L